Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Background Enfortumab vedotin (EV) is an antibody‐drug conjugate showing significant overall survival (OS) benefit versus chemotherapy for patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC) in EV‐301. This subgroup analysis was conducted to further analyze...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer medicine (Malden, MA) Vol. 12; no. 3; pp. 2761 - 2771
Main Authors:	Matsubara, Nobuaki, Yonese, Junji, Kojima, Takahiro, Azuma, Haruhito, Matsumoto, Hiroaki, Powles, Thomas, Rosenberg, Jonathan E., Petrylak, Daniel P., Matsangou, Maria, Wu, Chunzhang, Campbell, Mary, Yamashiro, Mayumi
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01.02.2023 John Wiley and Sons Inc Wiley
Subjects:	Antibodies, Monoclonal, Humanized - therapeutic use antibody‐drug conjugate Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bladder cancer Cancer therapies Carcinoma, Transitional Cell - pathology Cell cycle Chemotherapy Diabetes Drug dosages East Asian People enfortumab vedotin FDA approval Humans Japanese Metastases Metastasis metastatic Monoclonal antibodies Paclitaxel Patients Population Population studies Safety Scintigraphy Survival Targeted cancer therapy Urinary Bladder Neoplasms - pathology Urothelial carcinoma United States > US Japan antibody-drug conjugate urothelial carcinoma metastatic Japanese enfortumab vedotin
ISSN:	2045-7634, 2045-7634
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!